Investors

Press Releases

Date Title View
Toggle Summary Tetraphase Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass. , July 26, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that it has commenced an underwritten offering
View HTML
Toggle Summary Tetraphase Announces Positive Top-Line Results from Phase 3 IGNITE4 Clinical Trial in Complicated Intra-Abdominal Infections
̶   IV Eravacycline Achieves Primary Endpoint in Second of Two Pivotal Trials in cIAI  ̶ ̶   Company Proceeding with Regulatory Submissions in Europe in 3Q 2017 and U.S. in 1Q 2018   ̶  ̶  Ongoing Phase 3 IGNITE3 Clinical
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces Positive Phase 1 Single-Ascending Dose Data for Antibiotic Pipeline Candidates
Both TP-6076 and TP-271 Demonstrated Favorable Pharmacokinetic and Safety Profiles, Supporting Advancement into Multiple-Ascending Dose Studies
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference
WATERTOWN, Mass. , May 30, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present Antibiotics Pipeline Data at ASM Microbe 2017
Eleven Abstracts Selected for Presentation, Including Four Highlighting Pharmacokinetic and Global Surveillance Data for Eravacycline TP-6076 Phase 1 Single-Ascending Dose Data Selected for Oral Presentation; TP-271 Phase 1 Single-Ascending Dose Data to be Featured in Poster Presentation WATERTOWN,
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Recent Highlights
WATERTOWN, Mass. , May 04, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the first quarter ended
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
WATERTOWN, Mass. , April 21, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced seven data presentations at the 27 th
View HTML
Toggle Summary Tetraphase Pharmaceuticals Completes Enrollment of IGNITE4 Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
 Accelerated Timelines for Both Top-line IGNITE4 Eravacycline Data and MAA filing in Europe ; Both Now Expected in 3Q 2017   IGNITE4 Results to Support U.S. NDA Filing for IV Eravacycline in cIAI  WATERTOWN, Mass. , April 03, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc.
View HTML
Toggle Summary Tetraphase Pharmaceuticals' TP-6076 Selected by CARB-X to Receive $4 Million in Research Funding
Funding initiative focused on urgent public health crisis of antibiotic resistance
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
WATERTOWN, Mass. , March 27, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML